~~<i id='18ED2F8D48'><strike id='18ED2F8D48'><tt id='18ED2F8D48'><pre id='18ED2F8D48'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-10-01 20:29:14 Page View：3

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine
Next article： What does generative AI mean for health care? We asked experts

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Synthetic human embryos? Researchers say term is overblown

Amouseembryomodelcreatedentirelyfromstemcells.Scientistshavesinceusedsimilarsystemstobuildmodelsofhu

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

'The Exorcist' director William Friedkin dead at 87

1:29DirectorWilliamFriedkinposesforportrait,July01,2019inMilan.RosdianaCiaravolo/GettyImages,FILEWil